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Abstract 
Fbxo7/PARK15 has well-defined roles, acting as part of a Skp1-Cul1-F box protein (SCF)-type 
E3 ubiquitin ligase and also has SCF-independent activities. Mutations within FBXO7 have 
been found to cause an early-onset Parkinson’s disease, and these are found within or near 
to its functional domains, including its F-box domain (FBD), its proline rich region (PRR), and 
its ubiquitin-like domain (Ubl). We highlight recent advances in our understanding of Fbxo7 
function in Parkinson’s disease, with respect to these mutations and where they occur in the 
Fbxo7 protein.  We hypothesize that many of Fbxo7 functions contribute to its role in PD 
pathogenesis.  
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 Parkinson’s disease (PD) is the second most common neurodegenerative disease; it 
has been estimated that in 2005, the number of individuals over age 50 afflicted with PD 
was between 4.1 and 4.6 million in the 15 most populous countries in the world [1]. The 
majority of PD cases are sporadic and idiopathic with a median age of onset of 68. Men 
stand a greater risk of developing PD [2, 3], and some genetic factors and environmental 
influences, like head trauma, exposure to pesticides, and certain foods, are also associated 
with a higher risk for PD [4]. Currently, there are no good diagnostic biomarkers for the early 
stages of disease, and there is also no cure.  
 PD is characterized by the loss of dopamine (DA)-producing neurons in the 
substantia nigra pars compacta, although pathology is not restricted to this site. Diagnosis 
depends on the presence of specific clinical symptoms and signs including a resting tremor, 
rigidity, bradykinesia, and postural instability, and is often accompanied by an array of non-
motor features, only some of which take their origin from the dopaminergic nigrostriatal 
pathway. Post-mortem, the disease is characterized histopathologically by the presence of 
intra-cytoplasmic protein aggregates known as Lewy bodies (LBs), which contain α-synuclein 
among other proteins.  
 However, PD is not exclusively a disease of old age. Approximately 5-10% of sufferers 
are under the age of 40, and among these patients there are a discrete number of genes 
that have been linked to the development of disease [5], and which are the subject of other 
articles in this issue. One example of a rare mutation that is associated with a juvenile 
Parkinsonian-pyramidal disease (PPD) is PARK15, more commonly known as FBXO7 (F-box 
protein only 7). The clinico-pathological symptoms of PPD (otherwise known as Pallido-
pyramidal disease) first described by Charles Davison in 1954, suggested involvement of 
neuronal pathways that descend through the pyramidal tract, including Babinski sign and 
hypertonic spasticity [6]. These are distinct from the extra-pyramidal symptoms 
characteristic of PD, such as those listed above, which were also evident in these patients. 
However, more recently Horstink, et al. have brought into question the classification of PPD 
as a distinct clinical syndrome by suggesting that most pyramidal signs can be explained by 
other affected pathways; an idea supported by a lack of pallido-pyramidal degeneration in 
PPD patients [7]. A full pathological description of FBXO7 PPD is as yet unavailable, but 
these patients are Parkinsonian and respond to L-Dopa, and so must have pathology that is 
relevant to PD [8]. In addition, Fbxo7 protein is found in LBs of patients with sporadic 
disease, hinting at its involvement in idiopathic cases [9]. So although Fbxo7-associated 
disease is rare, research into this monogenic disease may reveal pathological changes that 
also underlie the development of sporadic PD. This review will describe the mutations in 
FBXO7 that are associated with disease to date, the functional domains in which they occur, 
and the insight they give into the potential mechanisms of neurodegeneration. 
 
Pathogenic mutations in FBXO7 map to particular functional domains 
 Disease-linked mutations in FBXO7 have now been found in several families from 
countries across Europe and the Middle East [10-14]. These mutations cause a juvenile-
onset PD frequently with pyramidal tract symptoms, such as Babinski sign and spasticity 
[12]. Other symptoms in PARK15 patients can also include tics and chorea, expanding the 
phenotypic spectrum associated with its mutation [13]. Mutations are inherited recessively, 
suggesting they produce a hypomorphic protein or cause a loss of function. Whereas most 
research on Fbxo7, prior to the first PD related report in 2008, investigated its role as a cell 
cycle and proteasome regulator, these findings raise questions about its cell-type specific 
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role in neurons. The use of high density whole-genome SNP arrays on an Iranian family, 
several members of which have Parkinsonian-pyramidal syndrome (PPS), enabled the 
discovery of the first homozygous missense mutation within FBXO7 (p.R378G) [12]. Other 
mutations reported shortly thereafter (Table 1), include a homozygous truncating p.R498X 
mutation in Italian, Turkish and Pakistani families [10, 11], and a compound heterozygous 
splice-site variant (IVS7 + 1G/T) and point mutation (p.T22M) in a Dutch family [10]. In the 
above instances, both copies of FBXO7 are mutated, but single allele changes have also 
been found. For example, a heterozygous p.R481C substitution has been found in an Italian 
family with homozygous p.G877R mutation in PARK9 [15]. In addition, single heterozygous 
amino acid substitutions (p.I87T and p.D328R) are present in two cases of early-onset PD in 
Taiwan [16]. 
 
Table 1. List of protein coding FBXO7 SNPs associated with PD or other clinical parameters. 
 
Mutation Domain  Notes References 
T22M Ubl - Compound heterozygous mutation with splice site 
IVS7 + 1G/T mutation found in Dutch family 
- Compromises Parkin binding and cellular location, 
as well as reducing expression levels when present 
with IVS7 + 1G/T. 
[10, 45, 46] 
Y52C Ubl - Potentially protective against PD in Chinese and 
Taiwanese populations. 
[17] 
I87T Near Ubl - Found in early onset Taiwanese PD patient. 
- No functional data as yet. 
[16] 
M115I Near CDK6 - Associated with altered RBC parameters. 
- No association with PD. 
[17-19] 
D328R Between FP 
and F-box  
- Found in early onset Taiwanese PD patient. 
- No functional data as yet. 
[16] 
R378G Near F-box 
domain 
- Homozygous mutation found in Iranian family.  
- Compromised Skp1 binding and altered location. 
- No effect on NF-κB signalling. 
[12, 27, 37] 
R481C R(Ar)DP 
motif 
within PRR 
- Heterozygous compound mutation found with 
homozygous G877R PARK9 mutation in Italian 
family. 
- No functional data as yet. 
[15] 
R498X PRR - Homozygous truncating mutation found in multiple 
families. 
- Reduced protein expression seen in patients 
fibroblasts. 
- No effect on NF-κB signalling. 
- Reduced capacity to recruit Parkin to mitochondria. 
[10, 11, 13, 
14, 27, 45, 
46] 
 
Other SNPs in FBXO7 have also recently been identified in relation to idiopathic PD; an allele 
encoding for p.Y52C is associated with decreased risk of disease in Chinese and Taiwanese 
patients [17], whereas a non-coding IVS-329C>T variant is moderately associated with 
increased risk [16]. Other GWAS studies have identified SNPs in FBXO7 as being relevant for 
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measurable erythroid parameters, including one that causes a coding substitution (p.M115I) 
[18]. However, no significant association between this SNP and PD has been found [17, 19].  
 Mapping these pathogenic mutations and associated SNPs to different FBXO7 exons 
indicates that many of its functional protein domains may be affected to cause pathology; 
however, most of these alterations cluster in or around the N-terminal ubiquitin-like (Ubl) 
domain, or the C terminal F-box domain (FBD) and proline rich region (PRR) (Figure 1A). 
These changes in relation to function (Figure 2) will be discussed below.  
 
The F-box domain of Fbxo7 
 The F-box domain within Fbxo7 enables its interaction with Skp1 and was originally 
identified using bioinformatics and functional approaches [20-22]. The presence of this 
three α-helical motif defines Fbxo7 as an F-box protein (FBP), and allows Fbxo7, and 
presumably any FBP, to become part of a Skp1-Cul1-FBP (SCF) type E3 ubiquitin ligase. An 
exemplar crystal structure of the F-box domain of Skp2 in complex with the other SCF 
components is shown in Figure 1D [23]. Within Fbxo7 isoform 1, its F-box domain is 
approximately two thirds along the length of the primary sequence, spanning amino acids 
335-372. Fbxo7 is the fifth most abundant SCF ligase in cultured cells, as assayed by 
quantitative mass spectrometry analysis of CUL1 binding partners [24]. This abundance 
notwithstanding, to date there are just four published substrates of SCFFbxo7. These include 
Hepatoma UpRegulated Protein (HURP) [25] and the NF-κB signaling pathway proteins, 
cIAP1, TRAF2 and NRAGE [26-28]. The first target of Fbxo7 mediated ubiquitination to be 
identified was HURP, a mitotic spindle protein that can regulate chromosome congression 
and is a proto-oncogene in hepatocellular carcinoma [29, 30]. Ubiquitination of HURP by 
SCFFbxo7 leads to its proteasomal degradation. However, unusually for an F-box protein, 
ubiquitination of the remaining substrates by SCFFbxo7 does not lead to their degradation, 
suggesting that alternative ubiquitin chains are formed on these substrates rather than the 
canonical K48-linked poly-ubiquitination that marks proteins for proteasomal degradation. 
In fact, it has been shown that poly-ubiquitination of NRAGE (Neurotrophin Receptor-
Interacting MAGE Homolog) by SCFFbxo7 is via K63-linked ubiquitin, indicating that SCFFbxo7 is 
able to catalyze different types of ubiquitin chain linkages [28]. Further research is required 
to determine what governs these differences that so profoundly affect the fate for SCFFbxo7 
substrates. It is possible that it may be due to differences in the manner in which substrates 
engage with the SCFFbxo7 ligase or its ability to recruit a variety of E2 enzymes that dictates a 
particular chain linkage. It will also be interesting to determine whether cIAP (cellular 
Inhibitor of Apoptosis) and TRAF2 (TNFα Receptor Associated Factor 2) are modified by K63-
linked ubiquitin chains impacting their function. These ubiquitination events generally lead 
to changes in a substrate’s function, localization and/or binding to other effectors [31]. In 
addition, poly-ubiquitination of proteins by K63-linked ubiquitin chains can also lead to their 
degradation in a proteasome-independent manner. For example, p62/SQSTM1 and ESCRT0 
complexes preferentially bind K63-linked poly-ubiquitinated proteins to target them to 
lysosomes, leading to their degradation via autophagy [32, 33]. In the case of NRAGE, Fbxo7 
facilitates its ubiquitination to promote its inclusion into active NRAGE–TAK1–TAB1 
complexes, leading to elevated NF-κB signaling [28]. The inflammatory NF-κB pathway, 
implicated in PD and other neurodegenerative diseases such as Alzheimer’s disease, is 
highly dependent on ubiquitination for its coordination [34]. Many proteins in this pathway 
are ubiquitinated, with various consequences, including degradation of inhibitors and 
cleavage of precursor proteins to their active forms via the proteasome, and activation of 
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protein complexes such as inhibitor kappa B kinase (IKK). Unlike NRAGE, the functional 
consequence of cIAP1 and TRAF2 ubiquitination by Fbxo7 is inhibition of NF-κB signaling 
[27]. Upon tumor necrosis factor-α (TNFα) stimulation, cIAP1 and TRAF2, which are both E3 
ligases, are recruited into TNF-receptor signaling complexes (TNF-RSC), leading to K63-linked 
ubiquitination of receptor interacting protein 1 (RIP1) activating the IKK signalosome [35, 
36]. However, SCFFbxo7 ubiquitination of cIAP1 and TRAF2 decreases their ability to 
ubiquitinate RIP, thereby inhibiting NF-κB signaling [27]. Although aberrant NF-κB signaling 
suggests an intriguing potential explanation for Fbxo7 pathogenesis, initial investigation of 
mutant R378G and R498X alleles of Fbxo7 showed no effect on NF-κB signaling [27]. Why 
Fbxo7 both positively and negatively regulates NF-κB signaling remains unclear. These 
differential effects may stem from cell-type specific effects, but it highlights the role of 
Fbxo7 as a scaffold that integrates upstream signaling events to effect disparate outcomes.  
 One alternate hypothesis to explain Fbxo7 pathology is that mutations in this F-box 
protein, which specifies protein ubiquitination, disables its enzymatic activity leading to 
toxic accumulation of a particular but as yet unknown protein, causing subsequent 
pathology. In fact, one of the homozygous mutations, p.R378G, impairs the ability of Fbxo7 
to function as an FBP, by reducing its ability to bind to Skp1 [37]. This mutation results in a 
change in protein sequence from a positively charged arginine to a smaller, amphoteric 
glycine residue. As this residue falls six amino acids outside of the boundaries of the F-box 
domain, this change may cause a conformational change that impinges on Skp1 binding or 
may result in fewer potential hydrogen bonds needed to stabilize Skp1 binding. Regardless, 
the outcome of this reduced interaction would be to decrease ubiquitination of all Fbxo7 
substrates, one or more of which is thought to be critical for PD. An additional consideration 
is that Nelson and Laman also found that the p.R378G mutation induces a subtle change in 
subcellular location of Fbxo7, causing it to be more cytoplasmic [37]. This is likely due to the 
requirement for Skp1 binding to Fbxo7 to promote its accumulation in the nucleus during S-
phase of the cell cycle. A nuclear export sequence overlaps the start of the F-box domain, 
setting up a competitive relationship between Skp1 binding and binding to the nuclear 
export protein CRM1. Since Fbxo7 p.R378G has a reduced capacity to bind Skp1, this 
consequently increased binding to CRM1 causing its export from the nucleus and 
accumulation in the cytoplasm. Altering the concentration of Fbxo7 and by extension active 
SCFFbxo7 ligase in different subcellular compartments may reduce its ubiquitination of 
nuclear and cytoplasmic substrates and also favor its non-canonical interactions, and either 
or both of these outcomes may contribute to pathogenesis.  
 In addition to the p.R378G mutation located downstream of the F-box domain, a 
heterozygous p.D328R mutation was discovered in an early-onset PD patient from Taiwan 
[16]. This amino acid is located seven amino acids in front of the F-box domain, and near the 
dimerizing Fbxo7-PI31 (FP) domain (see below). This substitution changes a negatively 
charged aspartic acid residue to a positively charged arginine and Lin, et al. hypothesize that 
this alteration may change the biochemical properties of the protein by affecting proton 
translocation or protein stability [16]. Although it is not known whether this SNP is 
pathogenic or disease-modifying, it would be interesting to test whether it causes 
perturbations to Skp1, CRM1, or PI31 interactions similar to the p.R378G mutation.  
 
The proline rich region (PRR) of Fbxo7 
 Fbxo7 is part of the Fbxo ‘other’ sub-family of FBPs, differing from those containing 
leucine rich repeats (Fbxl family) and WD40 domains (Fbxw family). Members of the Fbxo 
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family contain a variety of protein interacting domains to recruit substrates, such as F-box-
associated domains (FBA), RNase inhibitor-like motifs (RNI-like), and, in the case of Fbxo7, 
an N-terminal Ubl domain from amino acids 1-78 and a C-terminal PRR from amino acids 
423-522 (Figure 1A). Initial studies investigating HURP ubiquitination and degradation found 
that Fbxo7 binds HURP using its PRR, suggesting this region mediates substrate interaction 
[25]. Mapping an interaction domain for cIAP1 has not been directly undertaken, but Hsu, et 
al. and Chang, et al. used Fbxo7 isoform 2 to test for the ubiquitination of HURP and cIAP1, 
respectively. Isoform 2 of Fbxo7 lacks the Ubl domain of isoform 1, and has an alternative 12 
amino acid sequence at the start, demonstrating the Ubl is not required for binding to these 
two substrates.  
 The PRR domain is so named because of its high percentage of proline residues; 27% 
of the PRR is proline, compared to 6% in the rest of Fbxo7 and 6% throughout the entire 
human proteome [38]. Many of these proline residues are found in a PxxP formation which 
is a consensus sequence capable of binding Src Homology 3 (SH3) containing proteins, and 
may therefore potentially aid in protein-protein interactions between Fbxo7 and its 
substrates. The PRR is predicted to be largely unstructured, however it does contain a highly 
conserved R(Ar)DP motif, where Ar equals any aromatic residue [39]. A function for this 
motif has not yet been reported. Intriguingly, in patients with homozygous PARK9 
mutations, who develop an atypical juvenile parkinsonism called Kufor-Rakeb syndrome, a 
heterozygous mutation in FBXO7 targeting this conserved cluster of amino acids is also 
found [15]. This point mutation causes an p.R481C substitution, however the significance of 
this change has not yet been shown as it is also present in healthy family members. 
Although this SNP may be coincidental, it is possible that Fbxo7 activity may modify the 
disease phenotype along with other, as yet unidentified, mutations [15].  
 As well as mediating interactions with ubiquitination substrates, the PRR also forms 
part of a bi-partite binding domain for CDK6 interaction. The other region directly 
interacting with CDK6 is an unstructured region (amino acids 129-168) upstream of the FP 
domain and close to the p.M115I SNP associated with erythroid parameters. Binding of 
Fbxo7 to CDK6 does not change its expression levels, but rather enhances CDK6 activity, 
suggesting Fbxo7 acts as a molecular scaffold for cyclin/CDK complex assembly [20]. In 
addition to its ability to bind CDK6, Fbxo7 also interacts with a CDK inhibitor p27 [20]. p27 
inhibits CDK1/2 complexes, yet also acts as an assembly factor for CDK4/6 complexes at 
physiological levels [40]. p27 can independently bind Fbxo7, resulting in its stabilization and 
elevated protein expression [20]. Fbxo7 interaction with cell cycle proteins precipitates 
either pro- or anti-proliferative effects, depending on the cell type (Figure 2) [20, 41, 42]. 
Whether this non-canonical ability of Fbxo7 to influence cell cycle proteins has any role in 
post-mitotic neurons remains to be determined; however Fbxo7 may impact on adult 
neurogenesis, which is highly dependent on CDK6 and p27 [43, 44]. 
 One repeatedly isolated pathogenic mutation in FBXO7 is the homozygous nonsense 
p.R498X mutation, which introduces a premature stop codon removing the final 24 amino 
acids of the protein. Studies using fibroblasts isolated from FBXO7/PARK15 patients suggest 
these mutations primarily affect the levels of protein expression [45]. Patient fibroblasts 
with homozygous p.R498X mutations showed a lack of Fbxo7 protein expression despite 
normal mRNA levels, and heterozygous p.R498X fibroblasts showed reduced expression 
compared to control cells. It will be necessary to see if a similar protein expression pattern is 
evident in neurons bearing these mutant alleles. This will become feasible through the use 
of technologies such as CRISPR to introduce pathogenic mutations at the endogenous 
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FBXO7 locus or iPS cells generated from FBXO7/PARK15 patients differentiated into 
neurons. Nevertheless, these findings suggest that the p.R498X mutation translates to a loss 
of Fbxo7 expression and function for the patient.  
 In contrast to these findings in patient fibroblasts, experiments using exogenously 
expressed proteins in neuronal SHSY-5Y cells and a number of other cell types showed that 
Fbxo7-R498X is more robustly expressed than its WT counterpart, suggesting that this 
variant is more stable (our unpublished observations and [46]). This suggests that the C-
terminus may promote Fbxo7 turnover, perhaps by providing a degron for its auto-
ubiquitination, or ubiquitination by other SCF complexes. Fbxo7 has been found to interact 
with Parkin and PINK1 via its Ubl domain (see below), and through these interactions, 
facilitate Parkin recruitment and promote mitophagy. In experiments to test the 
mechanistic defect of individual PD-associated alleles in mitophagy, including p.R498X, it 
was shown that Fbxo7-R498X is unable to substitute for WT Fbxo7 in Parkin recruitment to 
mitochondria, despite its binding more efficiently to Parkin than WT [46]. In the same study, 
it was reported that Fbxo7-R498X cannot rescue Parkin loss in flies whereas WT Fbxo7 can 
[46]. These data suggest the C-terminus of Fbxo7 either stabilizes the interaction with Parkin 
at the mitochondria, or has other essential functions such as substrate recruitment and/or 
ubiquitination to enable mitophagy. One might predict based on these finding that patients 
with Fbxo7 p.R498X would be less able to utilize the PINK1-Parkin mitophagy pathway 
resulting in defective mitochondrial quality control. Experiments using physiologically 
relevant cell types and levels of expression are needed to reconcile the different findings 
seen in different cell culture systems.  
 
The FP domain of Fbxo7 
 The FP (Fbxo7/PI31) domain is a globular domain located centrally within Fbxo7 and 
enables its interaction with PI31, a protein that interacts directly with the proteasome. PI31 
was cloned by two independent methodologies as an interaction partner for Fbxo7: via 
affinity purification from a column of GST fused to Fbxo7 amino acids 129-398, and in a 
yeast two-hybrid screen using the same sequences from Fbxo7 as bait [39]. A sequence 
alignment of PI31 and Fbxo7 revealed their relatedness at a sequence organization and 
structural level. They have an equivalent FP domain, from 180-324 in Fbxo7 and 1-151 in 
PI31, and a PRR with extended secondary structure at their C-termini. As mentioned above, 
the PRR of Fbxo7 is thought to play a role in substrate recruitment. Within PI31, a conserved 
HbYX motif (Hb=hydrophobic; X=any amino acid), which is usually present is proteasome 
activators, is located at the extreme end of its PRR domain and mediates its binding to the 
-subunits of the 20S barrel [47-49]. This motif is not present in the PRR of Fbxo7. PI31 also 
contains the highly conserved R(Ar)DP motif found in Fbxo7, also within its PRR, highlighting 
the sequence similarities between the two proteins.  
 
The function of PI31 and its interaction with Fbxo7 
 The function of PI31 has been tested in studies in mammalian cells, yeast, and flies; 
however, there appear to be disparities in its function when tested in different assays. For 
example, PI31 demonstrates inhibitory activity towards the 20S proteasome when tested in 
vitro, stimulatory effects on 26S proteasomes in vitro, and variable effects in cells. It was 
originally identified alongside the 11S and 19S ‘lid’ activators in a screen for modulators of 
20S proteasome activity [50]. It acted a potent competitor of PA28-mediated activation of 
the 20S proteasome in in vitro assays with proteasomes isolated from cells, by competitively 
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inhibiting the 19S activator [48]. In addition, it can also directly impact on proteasomal 
activity as evidenced by recombinant PI31 inhibiting 20S proteasome hydrolysis of peptides 
in similar assays [47]. These in vitro characterizations explain the naming of this protein as 
proteasome inhibitor 31kD. However, further experimentation in intact cells reveals a more 
complex story. In the yeast S. cerevisiae, the PI31 orthologue, Fub1 does not inhibit 20S 
proteasome activity, but instead appears to act as a positive regulator of proteasome 
assembly or activity, since it becomes essential for viability if the proteasome chaperone 
Pba4 is deleted [51]. Furthermore, the synthetic lethality of the double deletion of Fub1 and 
a Pba4, can be suppressed by deletion of the N-terminus of β7 subunit of the proteasome, 
which allows its partial activation. These findings indicate a positive regulatory role for Fub1 
in enabling proteasome activity in yeast. No Fbxo7 homologues exist in yeast. 
 Drosophila encodes both a PI31 homologue (DmPI31) and an orthologue of Fbxo7, 
termed nutcracker. A major difference between the fly and mammalian Fbxo7 proteins is 
that nutcracker does not contain a C-terminal PRR, ending abruptly after its F-box domain, 
and the overall sequence homology between nutcracker and Fbxo7 is low (28% identity, 
45% similarity). Moreover, human Fbxo7 cannot complement nutcracker function, as its 
expression does not rescue the sterility of nutcracker male flies [46]. That notwithstanding, 
there is strong evidence that DmPI31 and nutcracker show an interdependent regulation of 
proteasomal activity [52, 53]. Nutcracker is characterized as a protein that has grossly 
similar activities to its mammalian counterpart: it forms part of an SCF, interacts with an 
apoptosis-regulator called Bruce, binds DmPI31, and is required for male fly fertility. 
Interestingly, DmPI31 binds nutcracker via an interface that is also used by mammalian 
Fbxo7 and PI31 (see structures below). Nutcracker does not promote the ubiquitin-
mediated degradation of DmPI31, but rather stabilizes DmPI31 levels and together their 
activities promote sperm production via the activation of caspases and an enhancement of 
proteasome activity [52, 53]. Thus, in contrast to its mammalian counterpart, DmPI31 
activates 26S proteasomes in vitro, and like the yeast Fub1, DmPI31 also appears to enhance 
overall proteasome activity in cells [52].   
 Recently, a study of PI31 in human cells (HEK293 and HeLa cells) demonstrated no 
effects on overall proteasome content or activity upon its increased or decreased expression 
[49]. This may be due to the fact that the majority of ectopic PI31 in mammalian cells in this 
study was not found to be associated with the 26S proteasome [49]. It may be the case that 
PI31 is only utilized under specific conditions, in particular cell types (e.g. in testes in the 
adult fly), or is induced by explicit signaling to the proteasome. Support for this idea comes 
from a study by Zaiss, et al. who reported that PI31 overexpression in murine MEC cells also 
did not inhibit proteasome-mediated proteolysis [54]. Instead it interfered with the 
production and maturation of immunoproteasomes (ImP) in response to interferon γ (IFNγ) 
and consequently affected the processing and presentation of ImP-dependent epitopes on 
MHC class I [54]. The ImP is a variant of the constitutive proteasome, wherein the catalytic β 
subunits are replaced with IFNγ inducible subunits, β1i (LMP2), β2i (MECL1), and β5i (LMP7), 
and the 19S ‘lid’ is replaced with an 11S ‘lid’ made from PA28 α and β subunits [55]. These 
subunit replacements confer altered cleavage specificities to the ImP and also supra-normal 
activity that boosts proteolysis under stress conditions, including viral infection and 
oxidative or metabolic stress [56]. In the context of neurodegenerative disease, the ImP may 
have particular relevance as it is selectively able to degrade oxidized proteins [56, 57], and 
an increased capacity to degrade damaged proteins may diminish the formation of protein 
aggregates [52].  
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3D structures of the FP domains of Fbxo7 and PI31 
The structures for the homologous FP domains of both Fbxo7 and PI31 have been 
solved [39, 58, 59]. This domain appears only within these two proteins, and no other solved 
protein structures appear to have their particular topology. The FP domain of PI31 is 
approximately 40 x 28 x 25 Å in size and consists of an α/β-fold with a central five-stranded 
anti-parallel βsheet flanked by two N-terminal α-helices and three C-terminal α-helices. 
The -helices pack against one face of the -sheet, like a fist against a palm, leaving the -
sheet face openly accessible [39]. Gel filtration of cell lysates indicate that the PI31 FP 
protomer exists predominantly in a dimeric state. Its homo-dimerization takes place through 
residues in the first -helix, and this is supported by the fact that mutation of Val6 in helix 
1 prevents this. There is a hydrophobic patch located on the surface of the -sheet, 
consisting of residues L64, I83, V85, and I90, which play a critical role in mediating protein-
protein interactions between mammalian and Drosophila PI31 and Fbxo7 [39, 52]. Point 
mutations in PI31 at I83 and I90 are sufficient to abrogate their hetero-dimerization. The 
residue equivalent to I83 of PI31’s FP domain within the -sheet of Fbxo7’s FP domain is 
V253. When this amino acid is mutated, it prevents Fbxo7 hetero-dimerization with PI31 
and its own homo-dimerization, indicating that the larger -sheet surface is used for Fbxo7 
dimerizing protein-protein interactions [39].  
Recently, the crystal structure of the FP domain within Fbxo7 was reported (Figure 
1C-i), and it bears high structural similarity with a comparable overall fold to that of PI31 
[58, 59].  Two additional well-structured loops in Fbxo7 were described: one of 9 amino 
acids in length between  helices 3 and 4, and one of 17 amino acids between -strands 
1 and 2. The C-terminal end of the FP domain in Fbxo7, comprising helix 5 and strands 
3, 4, 5, is longer and more extended, giving more structure to this region. The striking 
hydrophobic patch observed in the FP domain of PI31 which mediated its hetero-
dimerization with Fbxo7 appears conserved within the FP domain of Fbxo7. Most of the 
residues of helix 2 of Fbxo7 are hydrophobic, including 11 amino acids starting at amino 
acid 198 (ALIVLIHLLML). These amino acids, along with multiple others comprise its 
hydrophobic core, which gives it a strong, tightly packed structural stability. This compact, 
stable structure contributes to the two conformations adopted for inter-molecular 
interactions of Fbxo7’s FP protomer, described as an ‘ interface’ due to the fact that -
helices in one protomer and -strands in the other protomer are proposed to mediate 
interactions (Figure 1C-ii) [58]. This contrasts the exclusively -helical interface for homo-
dimerization or -sheet interactions for hetero-dimerizing interactions of the PI31 FP 
protomer [39]. The FP domain of Fbxo7 was predicted to be dimeric, and this is suggested to 
be due to the capacity of the FP domain to interact with adjacent FP domains using either 
the -helical or -sheet interacting surfaces located on opposing sides of the protomer. This 
capacity for dual use of the ‘ interface’ implies strongly that Fbxo7 homo-dimerizes, a 
common strategy for SCF-type ubiquitin ligases to regulate their activity, although this has 
not yet been tested for Fbxo7 in cells. What’s more, these studies raise the possibility for 
multimerization of Fbxo7, with or without PI31, in extended ‘hand-holding’ conformations. 
It has been recently suggested that such a hetero-dimer could form via an α/β interaction of 
the α-helical surface of Fbxo7 and the β-sheet surfaces of PI31 FP domains [58], but this has 
not been directly tested.  
In deducing the interacting interfaces for PI31 and Fbxo7, Kirk, et al. reported that 
PI31 can interact with Fbxo7 in the presence of Skp1, yet PI31 is not ubiquitinated [39]. 
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Similarly Bader, et al. reported that nutcracker does not ubiquitinate DmPI31 [52]. These 
findings leave open the possibility that PI31 could impact on SCFFbxo7 activity, potentially 
determining substrate choice or ubiquitin-chain linkage types, or on the non-canonical roles 
of Fbxo7. Alternatively or additionally, the high affinity interaction between mammalian 
Fbxo7 and PI31 suggests that Fbxo7 may stabilize PI31 levels, as is the case in flies, and/or 
affect PI31’s function regarding proteasomal regulation. However, any connection between 
PI31 and Fbxo7 in regulating mammalian proteasomal activity has not yet been reported. In 
either scenario it must also be appreciated that at least in cultured mammalian cells, the 
majority of PI31 and Fbxo7 appear in different subcellular locations. Endogenous PI31 has 
been shown to localize to the endoplasmic reticulum, while Fbxo7 shuttles between the 
nucleus and cytoplasm in a cell cycle-dependent fashion [37, 39, 54]. Any co-regulation by 
PI31 and Fbxo7 of proteasomal function may be spatially or temporally restricted to 
specialized cell types or particular circumstances that require high levels of proteasome 
activity. Since UPS dysfunction and protein aggregation are suspected factors in PD etiology, 
it is tempting to speculate that Fbxo7 regulation of the proteasome, possibly via its 
interaction with PI31, might also play a part in this disease. However, no mutations have 
been mapped within the dimerizing FP domain, although a p.D328R substitution which lies 
just beyond helix 5b and before the start of the NES/F-box domain has been recently 
found [16]. It remains to be seen if this affects dimerization, localization or ubiquitin ligase 
activity.  
 
The Ubl domain of Fbxo7 
 Fbxo7 is the only F-box protein among the Fbxo subfamily to contain at its N-
terminus a Ubl domain. This domain is present only in its longest and most abundant 
isoform 1, which is 522 amino acids in length. Its second isoform, of 443 amino acids, is 
encoded from an alternative 5’ exon and skips the exon which encodes the Ubl domain [42]. 
Ubl domains have both structural and sequence homology to ubiquitin, which is among the 
most highly conserved proteins. Of its 76 amino acids, only three residues diverge from 
mammals to plants and yeasts. Similar to the FP domain, ubiquitin forms a five strand β-
sheet, but it has only a single α-helix atop. Proteins which contain a Ubl domain are 
numerous and fall into two categories: those which are used in a fashion similar to ubiquitin 
such as SUMO, i.e. added as a modification and used in cell signaling, albeit distinct from 
ubiquitin itself, and those which do not act as protein modifiers, but instead incorporate this 
domain as an integral part of their sequence.  
 A generalized function for the Ubl domain among this second class of proteins is that 
they have the capacity to bind to the S5a/RPN10/PSMD4 subunit of 26S proteasomes. 
However, these Ubl domain-containing proteins escape proteasomal degradation [60, 61]. 
HHR23A/Rad23A is, for example, a well-characterized protein that contains a Ubl domain 
(the crystal structure for which is shown in Figure 1B) and transports poly-ubiquitinated 
proteins to the proteasome for their subsequent destruction [62, 63]. On the proteasome 
and within the lid, the S5a subunit is essential for this efficient degradation of poly-
ubiquitinated proteins via the recruitment of Ubl-domain containing proteins, which are 
recognized by the ubiquitin-interacting motif (UIM) in S5a. In addition, a second VWA motif 
within S5a restricts these UIM interactions from occurring except when it is associated with 
the 26S proteasome [64]. Fbxo7 falls into this latter category of Ubl-containing proteins, and 
can interact directly with the S5a subunit (our unpublished data).  One immediate prediction 
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of their association is that it would link ubiquitination of SCFFbxo7 substrates directly to the 
proteasome to promote their degradation. 
 Structural insight into the interaction of a Ubl domain within HHR23A to S5a has 
been undertaken for both the full length protein [65], and an isolated UIM domain [66]. In 
the Ubl domain, multiple residues within the five-stranded β-sheet (I9, L10, K47, L48, I49, 
K53, I54, L55, V73, M75), its connecting loops (E11, E12, G45, A51, S56, V59), and a C-
terminal residue (K78) are proposed to be important contributors to UIM binding. Among 
these is K53, the equivalent residue to K48 in ubiquitin that is important for poly-ubiquitin 
chain linkages [66]. Interestingly, this K53 is conserved within the Ubl of Fbxo7, and is near 
the Y52 residue which appears as a potential protective allele of Fbxo7 when substituted 
with cysteine. One possibility is that a p.Y52C mutation may affect Fbxo7 affinity for S5a and 
its interaction with the proteasome. By comparison, Parkin, like Fbxo7, is an ubiquitin ligase 
and contains an N-terminal Ubl domain that binds to S5a. The full length structure of Parkin 
has recently been solved [67, 68] and is discussed in detail elsewhere in this issue. One of 
the pathogenic mutations within the Ubl domain of Parkin (p.R42P) has been suggested to 
impair its interaction with the proteasome and this may contribute to Parkin-mediated 
pathology [69]. The effect of a p.Y52C substitution on Fbxo7 protein levels and/or on the 
SCFFbxo7 ubiquinome remains to be determined.    
 A definitive role for the Ubl domain of Fbox7 in direct interactions with both Parkin 
and PINK1 has recently been published. Burchell, et al. showed that Fbxo7 is recruited to 
mitochondria and plays a role in the PINK1/Parkin-regulated pathway for autophagic 
clearance of damaged or depolarized mitochondria [46]. The relationship between 
PINK1/Parkin and their control of mitophagy has been well documented and is also detailed 
in other articles in this issue. In brief, the current model is that PINK1 is activated by the loss 
of inner mitochondrial membrane potential which promotes its auto-phosphorylation and 
subsequent phosphorylation of Parkin on S65, within its N-terminal Ubl domain, which 
activates its E3 ubiquitin ligase activity and primes its mitochondrial translocation [70-73]. 
Parkin’s Ubl domain has been demonstrated to restrain its intrinsic auto-ubiquitination 
capacity through an intramolecular association with its C-terminus, indicating an auto-
inhibitory mechanism. Moreover, pathogenic missense mutations in Parkin including p.R42P 
and p.K48A disrupt this auto-inhibition, suggesting this interaction is important in PD [74]. 
Although the mechanism by which Fbxo7 participates in mitophagy remains to be 
determined, Burchell, et al. proposed that Fbxo7 may act as a scaffold to facilitate PINK1-
mediated phosphorylation and activation of Parkin, and also ubiquitinate its own specific, 
but as yet unknown, targets to promote mitophagy [46]. A pathogenic mutation, p.T22M 
within the Ubl interferes with Parkin binding, recruitment and subsequent mitophagy, and a 
p.T22M allele of Fbxo7 cannot rescue the mitophagy defect seen with knockdown of WT 
Fbxo7. The PINK1 binding site on Fbxo7 includes the Ubl domain and extends further along 
the protein, but its binding is not affected by the p.T22M mutation [46]. Interestingly, 
fibroblasts from patients with compound heterozygous p.T22M and IVS7 + 1G/T mutations 
show an absence of Fbxo7 isoform 1 expression, but not isoform 2, suggesting these 
mutations may also destabilize the protein, at least in fibroblasts [45]. It is tempting to 
speculate that given their similar enzymatic activities and Ubl domains at the N-terminus 
that Fbxo7 may, like Parkin, have an intramolecular interaction involving its Ubl domain that 
regulates its auto-ubiquitination and/or its ubiquitin ligase activity. Indeed the critical serine 
residue within ubiquitin and Parkin that is phosphorylated by PINK1 is present within Fbxo7. 
However, in a screen for substrates, Fbxo7 was not phosphorylated by PINK1 [71]. 
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Nevertheless, Fbxo7 was found to function downstream of PINK1 as Fbxo7 relocation was 
PINK1-dependent. Also the expression of Fbxo7 could not rescue the phenotypes associated 
with PINK1 silencing in mammalian cells or in Drosophila. The mechanistic basis for this is as 
yet unknown.  
 In addition to mitophagy regulation, another potential function for the Ubl domain in 
Fbxo7 may lay in the fact that the Ubl domains can aid in resolving or clearing protein 
aggregates. Evidence for this capacity for Ubl domains comes from a critical Ubl-UIM 
interaction between PLIC-1 and EPS15, AT3 and HSJ1a, which are known to be involved in 
the clearance of misfolded and aggregated proteins [75]. The presence of Fbxo7 in Lewy 
Bodies in idiopathic PD brain samples suggests they play some role at these sites of protein 
deposition. The capacity for multiple interactions of the Ubl domain affecting two suspect 
pathogenic pathways in PD may explain Fbxo7’s involvement in this disease.  
 
Concluding remarks 
 Fbxo7/PARK15 is a highly engineered, multi-functional protein with effects on 
multiple cellular pathways, including NF-κB and NGF signaling, cell cycle, proteasome 
regulation, and mitophagy, and with differential, sometimes contradictory, effects in 
specific cell types. This diversity of functions is likely to reflect its capacity to work as a 
networking hub that integrates cellular responses, either through its activities as an E3 
ligase or as a scaffolding platform. The identification of pathogenic mutations within its 
specific functional domains helps focus researchers on particular activities; however, it will 
undoubtedly be necessary to investigate their consequences in the relevant cell type and 
physiological setting(s) to understand their impact across the network of processes that 
Fbxo7 regulates. Fbxo7 regulation of multiple pathways implicated in the etiology of PD may 
explain why it is a PARK gene. Our challenge now is to find out the mechanism(s) and to 
exploit this understanding to benefit patients.  
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Figure 1. Human Fbxo7 protein structure. (A) Fbxo7 isoform 1 protein structure with 
structural domains, and clinically relevant SNPs highlighted above. A nuclear export signal 
within the F-box domain is in a lighter shade. Familial pathogenic PD mutations are T22M, 
R378G and R498X, a protective SNP is Y52C, and other SNPs identified in idiopathic PD 
patients (I87T, D328R and R481C) or associated with erythroid parameters (M115I) are also 
shown. (B-D) Exemplar crystal structures for domains within Fbxo7 are shown, with the N 
and C terminal labeled and α-helices and β-strands numbered in order. (B) Cartoon of the 
ubiquitin-like (Ubl) domain of hHR23A, as determined by X-ray crystallography (PDB ID: 
2WYQ). Reprinted with permission of the International Union of Crystallography [76]. (C) (i) 
Cartoon of the Fbxo7/PI31 (FP) interacting domain of Fbxo7, (ii) with a model of three Fbxo7 
FP domains binding via α/β interfaces (PDB ID: 4L9C and 4L9H). Reprinted with permission 
of Oxford University Press [59]. (D) Cartoon of the F-box domain of Skp2 (purple) showing 
three α-helices, overlaying Skp1 (blue), and in complex with Cul1 (green) and Rbx1 (red) 
(PDB ID: 1LDK). The α-helices of one cullin-repeat motif are labelled A-E, and the zinc 
molecules in Rbx1, which binds the C-terminal globular α/β domain (CTD) of Cul1, are in 
yellow. Reprinted with permission of Nature Publishing Group [23]. 
 
Figure 2. Functions of Fbxo7. Binding of proteins to Fbxo7 can result in various outcomes. 1) 
Fbxo7 can directly bind to PINK1 and Parkin at the mitochondrial membrane. A loss of 
mitochondrial membrane potential (↓Δψ) results in accumulation of PINK1 at the 
mitochondria, at which point Fbxo7 aids in the recruitment of Parkin and the induction of 
mitophagy. The pathogenic mutation T22M inhibits Fbxo7 binding to Parkin, and the R498X 
mutation inhibits Fbxo7/Parkin accumulation at the mitochondria. 2) Fbxo7 affects the cell 
cycle through its ability to stabilise active Cdk6/Cyclin D complexes or p27 levels, resulting in 
oncogenic and tumour suppressive properties respectively. 3) Fbxo7 binds directly to PI31 
which can have activating or inhibitory effects on the proteasome. A loss of proteasome 
regulation is believed to be an important factor in the pathogenesis of PD, resulting in 
cellular stress and protein aggregation; Fbxo7 involvement in this process is not known. 4) 
Fbxo7 functions as the substrate specifying subunit of SCF-type E3 ubiquitin ligases, involved 
in the transfer of ubiquitin from E2 enzymes to substrates. Fbxo7 can mediate the poly-
ubiquitination of HURP via K48 linkages, leading to its proteasomal degradation, and also of 
the NF-κB pathway components cIAP, TRAF2 and NRAGE, potentially via K63 linked 
ubiquitination. The functional outcome of these modifications changes NF-κB signalling. The 
R498X mutation may affect substrate recruitment, and the R398G mutation reduces Skp1 
binding.  
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